Literature DB >> 31885310

miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.

Zhenhua Hu1, Mingbo Cai1, Ying Zhang1, Lingling Tao2, Ruixia Guo1.   

Abstract

Autophagy, characterized by the elevator of autophagy-related gene 14 (ATG14) and the dysregulation of autophagy-related proteins, contributes to the cisplatin (DDP) resistance in ovarian cancer. Forkhead box protein P1 (FOXP1), which is a well-defined transcription factor, is reported to have the oncogenic effect on ovarian cancer. This study aims to identify the effect of miR-29c-3p/FOXP1/ATG14 pathway in regulating autophagy and DDP resistance in ovarian cancer. The expressions of miR-29c-3p, FOXP1, ATG14 and autophagy-related proteins were detected in DDP-sensitive ovarian cancer cell lines (SKOV3 and A2780) and DDP-resistant cell lines (SKOV3/DDP and A2780/DDP). Cell viability was detected using the MTT assay. The therapeutic effect of miR-29c-3p overexpression was observed in the xenograft model of nude mice.Compared with DDP-sensitive cells, miR-29c-3p was decreased in DDP-resistant cells, and an enhancement of FOXP1, ATG14, autophagy, and drug resistance was shown in DDP-resistant cells. The anti-resistant effect of miR-29c-3p was observed as overexpressing miR-29c-3p inhibited cell viability of DDP-resistant cells. Moreover, FOXP1 was a target of miR-29c-3p, which was confirmed by the luciferase reporter assay, and ATG14 was transactivated by FOXP1, which was confirmed by the ChIP assay. Overexpression of miR-29c-3p increased DDP sensitivity by downregulating FOXP1/ATG14 in vitro. The tumor volume was reduced after the injection of miR-29c-3p-overexpressing SKOV3/DDP cells in vivo. Overexpression of miR-29c-3p inhibited autophagy and DDP resistance partly via downregulating FOXP1/ATG14 pathway, suggesting miR-29c-3p as a novel target in overcoming DDP resistance in ovarian cancer.

Entities:  

Keywords:  ATG14; FOXP1; Ovarian cancer; autophagy; miR-29c-3p

Mesh:

Substances:

Year:  2019        PMID: 31885310      PMCID: PMC6961660          DOI: 10.1080/15384101.2019.1704537

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  38 in total

1.  MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3.

Authors:  Huijuan Wu; Zhenghua Xiao; Hua Zhang; Ke Wang; Wenxin Liu; Quan Hao
Journal:  Anticancer Drugs       Date:  2014-08       Impact factor: 2.248

2.  The autophagy-related protein LC3 is processed in stallion spermatozoa during short-and long-term storage and the related stressful conditions.

Authors:  I M Aparicio; P Martin Muñoz; G M Salido; F J Peña; J A Tapia
Journal:  Animal       Date:  2016-03-02       Impact factor: 3.240

3.  MicroRNA-152 inhibits ovarian cancer cell proliferation and migration and may infer improved outcomes in ovarian cancer through targeting FOXP1.

Authors:  Wen Qin; Wei Xie; Qinglin He; Tianwei Sun; Chaoguo Meng; Kunling Yang; Yuanfu Luo; Dongmei Yang
Journal:  Exp Ther Med       Date:  2017-11-17       Impact factor: 2.447

Review 4.  The autophagic paradox in cancer therapy.

Authors:  W K K Wu; S B Coffelt; C H Cho; X J Wang; C W Lee; F K L Chan; J Yu; J J Y Sung
Journal:  Oncogene       Date:  2011-07-18       Impact factor: 9.867

5.  Role of autophagy in cisplatin resistance in ovarian cancer cells.

Authors:  Juan Wang; Gen Sheng Wu
Journal:  J Biol Chem       Date:  2014-05-02       Impact factor: 5.157

6.  Expression analysis of microRNAs and mRNAs in ovarian granulosa cells after microcystin-LR exposure.

Authors:  Xiaoyan Li; Xin Zhuang; Tianchi Xu; Min Mao; Cong Wang; Yabing Chen; Xiaodong Han; Jiang Wu
Journal:  Toxicon       Date:  2017-02-02       Impact factor: 3.033

7.  TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer.

Authors:  Song-Fa Zhang; Xin-Yu Wang; Zhi-Qin Fu; Qiao-Hua Peng; Jian-Yang Zhang; Feng Ye; Yun-Feng Fu; Cai-Yun Zhou; Wei-Guo Lu; Xiao-Dong Cheng; Xing Xie
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

8.  Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer.

Authors:  Constanze Zeller; Robert Brown
Journal:  Ther Adv Med Oncol       Date:  2010-09       Impact factor: 8.168

9.  MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.

Authors:  Ningwei Li; Lingyun Yang; Hongjing Wang; Tao Yi; Xibiao Jia; Cen Chen; Pan Xu
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

10.  FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.

Authors:  Eun Jung Choi; Eun Jin Seo; Dae Kyoung Kim; Su In Lee; Yang Woo Kwon; Il Ho Jang; Ki-Hyung Kim; Dong-Soo Suh; Jae Ho Kim
Journal:  Oncotarget       Date:  2016-01-19
View more
  26 in total

1.  Sevoflurane attenuates cardiomyocyte apoptosis by mediating the miR-219a/AIM2/TLR4/MyD88 axis in myocardial ischemia/reperfusion injury in mice.

Authors:  Yan Li; Na Xing; Jingjing Yuan; Jianjun Yang
Journal:  Cell Cycle       Date:  2020-05-23       Impact factor: 4.534

Review 2.  Activation of SIRT-1 Signalling in the Prevention of Bipolar Disorder and Related Neurocomplications: Target Activators and Influences on Neurological Dysfunctions.

Authors:  Bidisha Rajkhowa; Sidharth Mehan; Pranshul Sethi; Aradhana Prajapati
Journal:  Neurotox Res       Date:  2022-02-14       Impact factor: 3.911

3.  Elevated mRNA Expression Levels of NCAPG are Associated with Poor Prognosis in Ovarian Cancer.

Authors:  Tao Xu; Menglu Dong; Zhi Wang; Hanning Li; Xingrui Li
Journal:  Cancer Manag Res       Date:  2020-07-14       Impact factor: 3.989

4.  Alantolactone and ZnO nanoparticles induce apoptosis activity of cisplatin in an ovarian cancer cell line (SKOV3).

Authors:  Shahriar Alipour; Ghader Babaei; Shiva Gholizadeh-Ghaleh Aziz; Somayeh Abolhasani
Journal:  Res Pharm Sci       Date:  2022-04-18

5.  Exosomal microRNA‑146a derived from mesenchymal stem cells increases the sensitivity of ovarian cancer cells to docetaxel and taxane via a LAMC2‑mediated PI3K/Akt axis.

Authors:  Liya Qiu; Jiakun Wang; Mei Chen; Fengyun Chen; Wenluo Tu
Journal:  Int J Mol Med       Date:  2020-06-05       Impact factor: 4.101

Review 6.  Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Kiavash Hushmandi; Mahshad Kalantari; Reza Mohammadinejad; Tahereh Javaheri; Gautam Sethi
Journal:  Int J Mol Sci       Date:  2020-06-03       Impact factor: 5.923

7.  MiR-29c-3p inhibits epithelial-mesenchymal transition to inhibit the proliferation, invasion and metastasis of cervical cancer cells by targeting SPARC.

Authors:  Ting Zou; Yan Gao; Mingrong Qie
Journal:  Ann Transl Med       Date:  2021-01

Review 8.  Small in Size, but Large in Action: microRNAs as Potential Modulators of PTEN in Breast and Lung Cancers.

Authors:  Asal Jalal Abadi; Ali Zarrabi; Mohammad Hossein Gholami; Sepideh Mirzaei; Farid Hashemi; Amirhossein Zabolian; Maliheh Entezari; Kiavash Hushmandi; Milad Ashrafizadeh; Haroon Khan; Alan Prem Kumar
Journal:  Biomolecules       Date:  2021-02-18

9.  Potential Role of miRNAs in the Acquisition of Chemoresistance in Neuroblastoma.

Authors:  Barbara Marengo; Alessandra Pulliero; Maria Valeria Corrias; Riccardo Leardi; Emanuele Farinini; Gilberto Fronza; Paola Menichini; Paola Monti; Lorenzo Monteleone; Giulia Elda Valenti; Andrea Speciale; Patrizia Perri; Francesca Madia; Alberto Izzotti; Cinzia Domenicotti
Journal:  J Pers Med       Date:  2021-02-07

10.  TUG1 enhances high glucose-impaired endothelial progenitor cell function via miR-29c-3p/PDGF-BB/Wnt signaling.

Authors:  Yang Li; Kangkang Zhi; Shilong Han; Xue Li; Maoquan Li; Weishuai Lian; Haijun Zhang; Xiaoping Zhang
Journal:  Stem Cell Res Ther       Date:  2020-10-15       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.